Cytek Biosciences
CTKB
52 hedge funds and large institutions have $572M invested in Cytek Biosciences in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 13 closing their positions.
122% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 9
0.51% more ownership
Funds ownership: 25.69% → 26.2% (+0.51%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 54 → 52 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
23% less capital invested
Capital invested by funds: $744M → $572M (-$172M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MGM
Miura Global Management
New York
|
+$18.9M |
| 2 |
BlackRock
New York
|
+$10.8M |
| 3 |
E
Ergoteles
New York
|
+$3.71M |
| 4 |
Renaissance Technologies
New York
|
+$2.28M |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RFA
Reilly Financial Advisors
La Mesa,
California
|
-$10.6M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.45M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$7.02M |
| 4 |
Millennium Management
New York
|
-$3.83M |
| 5 |
CCM
CAAS Capital Management
New York
|
-$2.14M |
CTKB Hedge Fund Activity: Q4 2021 in Review
52 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q4 2021, worth a combined $572M — down 23% from $744M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CTKB and 11 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 20 added.
The largest buyer was Miura Global Management, adding an estimated $18.9M. The largest seller was Reilly Financial Advisors, exiting entirely with an estimated $10.6M sold.
- 52 institutional investors held Cytek Biosciences (CTKB) as of Q4 2021, down from 54 in Q3 2021.
- Funds reported $572M of Cytek Biosciences stock for Q4 2021, down 23% quarter-over-quarter.
- 11 funds opened new Cytek Biosciences positions in Q4 2021 and 13 closed out, a net change of -2 holders.
- The largest Cytek Biosciences buyer in Q4 2021 was Miura Global Management, an estimated $18.9M added.
- The largest Cytek Biosciences seller in Q4 2021 was Reilly Financial Advisors, an estimated $10.6M sold.
Based on aggregated 13F filings for Q4 2021.